Hudson Bay Capital Management
ALNY icon

Hudson Bay Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hudson Bay Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$4.48M – 770
2024
Q1 		$4.48M Buy
+30,000
New +$5M 0.02% 322
2023
Q4 		– Sell
-19,900
Closed -$3.52M – 711
2023
Q3 		$3.52M Buy
+19,900
New +$3.8M 0.03% 374

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hudson Bay Capital Management's ALNY Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 53% in Q1 2026, selling an estimated $15.3M and leaving 40,000 shares worth $13.2M. The position accounts for 0.05% of the portfolio, ranked #262.

Hudson Bay Capital Management first reported a position in ALNY in Q2 2018 and has held it in 18 quarters since. The position peaked at $33.8M in Q4 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Hudson Bay Capital Management held 40,000 shares of Alnylam Pharmaceuticals worth $13.2M as of Q1 2026.
  • Hudson Bay Capital Management sold 45,000 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $15.3M.
  • Alnylam Pharmaceuticals made up 0.05% of Hudson Bay Capital Management's portfolio in Q1 2026, its #262 holding.
  • Hudson Bay Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2018 and has held it in 18 quarters since.
  • Hudson Bay Capital Management's Alnylam Pharmaceuticals position peaked at $33.8M in Q4 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.